| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1998;66:108-112
© 1998 The Society of Thoracic Surgeons
a Departments of Surgery, Anesthesia, and Laboratory Medicine, Montreal Heart Institute, Montreal, Quebec, Canada
Accepted for publication February 21, 1998.
Address reprint requests to Dr Carrier, Montreal Heart Institute, 5000 Bélanger St E, Montreal, Quebec, Canada H1T 1C8
e-mail: (carrier{at} icm.umontreal.ca)
Background. L-Arginine appears to improve myocardial protection during cardioplegic arrest in animal models.
Methods. To study the clinical effect and safety of L-arginine in humans, a phase I pilot study was performed with 50 patients who underwent coronary artery bypass grafting. We randomly assigned half to a treatment group, which received 1 g of L-arginine administered during the first 30 minutes of cardioplegic arrest induced by either warm or cold blood cardioplegia, and half to a control group, which did not receive L-arginine supplementation.
Results. Age, sex, and preoperative clinical status were similar in both groups. Seventeen patients of each group were administered intermittent warm antegrade blood cardioplegia, whereas the solution needed to be cooled to obtain complete standstill of the remaining eight hearts in each group. An internal thoracic artery graft to the left anterior descending coronary artery was performed in all patients. There was no death and no myocardial infarction in the treatment group, but there were one death and two infarctions in the control group. The amount of serial release of troponin I during the first 72 hours after the operation was similar between the L-arginine group and the control group (p > 0.05). Peak serum troponin levels averaged 4.9 ± 1.0 µg/L in the arginine group and 3.9 ± 1.0 µg/L in the control group (p > 0.05). A multivariate analysis of variance showed no effect of L-arginine (p > 0.05) but a significant effect of the temperature of the cardioplegic solution on the release of troponin I (p < 0.05). Serum troponin I levels averaged 2.2 ± 0.4 µg/L, 4.5 ± 0.4 µg/L, and 6.9 ± 0.4 µg/L in the patients with cold cardioplegia and 1.4 ± 0.3 µg/L, 2.4 ± 0.3 µg/L, and 3.3 ± 0.3 µg/L in the patients with warm cardioplegia 1, 2, and 6 hours, respectively, postoperatively.
Conclusions. The administration of 1 g of L-arginine during the first 30 minutes of blood cardioplegic arrest did not result in a decrease in the postoperative release of cardiac enzyme; however, cold cardioplegic arrest significantly increased the release of cardiac troponin I postoperatively. There was no significant side effect related to the addition of L-arginine to the cardioplegic solution.
This article has been cited by other articles:
|
|
 |
|
  L. Colagrande, F. Formica, F. Porta, A. Martino, F. Sangalli, L. Avalli, and G. Paolini Reduced Cytokines Release and Myocardial Damage in Coronary Artery Bypass Patients Due to L-Arginine Cardioplegia Supplementation Ann. Thorac. Surg., April 1, 2006; 81(4): 1256 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Korn, A. Kroner, J. Schirnhofer, S. Hallstrom, O. Bernecker, R. Mallinger, M. Franz, H. Gasser, E. Wolner, and B. K. Podesser Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 352 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Carrier, M. Pellerin, L. P. Perrault, D. Bouchard, P. Page, N. Searle, and J. Lavoie Cardioplegic arrest with L-arginine improves myocardial protection: results of a prospective randomized clinical trial Ann. Thorac. Surg., March 1, 2002; 73(3): 837 - 841. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
